{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:00:36Z","timestamp":1790456436546,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017366","name":"Key Research and Development Program of Heilongjiang","doi-asserted-by":"publisher","award":["2023ZX06C09"],"award-info":[{"award-number":["2023ZX06C09"]}],"id":[{"id":"10.13039\/100017366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014418","name":"Harbin Medical University Cancer Hospital","doi-asserted-by":"publisher","award":["JJZD2024\\u201316"],"award-info":[{"award-number":["JJZD2024\\u201316"]}],"id":[{"id":"10.13039\/100014418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303742"],"award-info":[{"award-number":["82303742"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62372141"],"award-info":[{"award-number":["62372141"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbcan.2026.189718","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:49:44Z","timestamp":1789602584000},"page":"189718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From molecular characteristics to clinical practice: current status and future prospects of immunotherapy for SMARCA4-deficient tumors"],"prefix":"10.1016","volume":"1881","author":[{"given":"Rina","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhe","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189718_bb0005","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/PAS.0000000000000173","article-title":"SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review","volume":"38","author":"Agaimy","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0010","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ng.3399","article-title":"SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas","volume":"47","author":"Le Loarer","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189718_bb0015","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41417-024-00732-4","article-title":"The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation","volume":"31","author":"Li","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bbcan.2026.189718_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cells10081920","article-title":"Perspectives and issues in the assessment of SMARCA4 deficiency in the management of lung cancer patients","volume":"10","author":"Armon","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189718_bb0025","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1158\/1535-7163.MCT-21-0433","article-title":"SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy","volume":"20","author":"Mardinian","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189718_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216022","article-title":"SMARCA4: current status and future perspectives in non-small-cell lung cancer","volume":"554","author":"Tian","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189718_bb0035","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189718_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032869","article-title":"BRG1: promoter or suppressor of cancer? The outcome of BRG1\u2019s interaction with specific cellular pathways","volume":"24","author":"Shaykevich","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189718_bb0045","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1038\/s41467-019-12573-z","article-title":"BRG1 attenuates colonic inflammation and tumorigenesis through autophagy-dependent oxidative stress sequestration","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189718_bb0050","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.21037\/tcr-22-1679","article-title":"Effectiveness of tislelizumab when combined with etoposide and carboplatin in patients with SMARCA4-deficient undifferentiated thoracic tumor: a case report","volume":"12","author":"Yang","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25063237","article-title":"Treatment of thoracic SMARCA4-deficient undifferentiated tumors: where we are and where we will go","volume":"25","author":"Longo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189718_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17162675","article-title":"Clinical characteristics and outcomes of SMARCA4-mutated or deficient malignancies: a systematic review of case reports and series","volume":"17","author":"Ohta","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189718_bb0065","doi-asserted-by":"crossref","first-page":"9813","DOI":"10.21037\/jtd-2025-2002","article-title":"Clinical characteristics and prognostic analysis of 22 cases of SMARCA4-deficient thoracic tumors: a retrospective observational study","volume":"17","author":"Yang","year":"2025","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.bbcan.2026.189718_bb0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jtho.2019.10.023","article-title":"SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas","volume":"15","author":"Rekhtman","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0075","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/CAD.0000000000001758","article-title":"Pembrolizumab treatment in SMARCA4-deficient nonsmall cell lung cancer: high tumor mutational burden and programmed death-ligand 1(+) expression on circulating tumor cells for real-time monitoring: a case report","volume":"36","author":"Deng","year":"2025","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.bbcan.2026.189718_bb0080","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2026.189718_bb0085","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0090","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(25)00429-2","article-title":"Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis","volume":"26","author":"Di Federico","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0095","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.21037\/tlcr-2025-921","article-title":"Immune checkpoint inhibitors have limited efficacy in SMARCA4-deficient non-small cell lung cancer","volume":"14","author":"Han","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0100","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.1007\/s00432-023-04806-y","article-title":"Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor","volume":"149","author":"Lin","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0105","doi-asserted-by":"crossref","first-page":"456","DOI":"10.5306\/wjco.v15.i3.456","article-title":"PD-1 antibody in combination with chemotherapy for the treatment of SMARCA4-deficient advanced undifferentiated carcinoma of the duodenum: two case reports","volume":"15","author":"Shi","year":"2024","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1399868","article-title":"A case of surgically treated non-metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report and literature review","volume":"14","author":"Yin","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.21037\/tlcr-24-567","article-title":"SMARCA4\/BRG1-deficient non-small cell lung cancer: clinical, imaging, pathological features, and follow-up results of 23 patients","volume":"14","author":"Wumener","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0120","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/modpathol.2017.11","article-title":"Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities","volume":"30","author":"Yoshida","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153794","article-title":"Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): patient characteristics, treatment, and outcome-a systematic review","volume":"15","author":"Wens","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2026.189718_bb0130","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s12105-022-01423-y","article-title":"SMARCB1 (INI1)-deficient sinonasal carcinoma with yolk sac differentiation showing co-loss of SMARCA4 immunostaining - a case report and literature review","volume":"16","author":"Ng","year":"2022","journal-title":"Head Neck Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0135","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10120-024-01510-9","article-title":"SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review","volume":"27","author":"An","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0140","first-page":"419","article-title":"SMARCA4-deficient rectal carcinoma with a sarcomatoid component: a case report, Clin","volume":"15","author":"Meda","year":"2022","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol33020107","article-title":"SMARCA4-deficient carcinomas of the small intestine: a systematic review","volume":"33","author":"Syed","year":"2026","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0150","article-title":"Case report: recognition and management of SMARCA4-deficient renal cell carcinoma","volume":"15","author":"Wang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0155","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000002512","article-title":"Primary cutaneous SWI\/SNF-deficient carcinomas: morphologic, immunohistochemical, and molecular analysis of seven cases","author":"Ronen","year":"2026","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0160","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s12029-024-01060-4","article-title":"SMARCA4-deficient undifferentiated esophageal carcinoma: a clinical case series and literature review","volume":"55","author":"Shweikeh","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13000-021-01091-6","article-title":"Undifferentiated colonic neoplasm with SMARCA4 germline gene mutation and loss of SMARCA4 protein expression: a case report and literature review","volume":"16","author":"Duan","year":"2021","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0170","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1177\/10668969231206575","article-title":"Primary undifferentiated gallbladder carcinoma with SMARCA4 deletion: a case report and review of the literature","volume":"32","author":"Xiaoxu","year":"2024","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0175","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/modpathol.2017.61","article-title":"SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior","volume":"30","author":"Sauter","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0180","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1007\/s00330-019-06017-x","article-title":"Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients","volume":"29","author":"Cromb\u00e9","year":"2019","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0185","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.pathol.2019.05.011","article-title":"Innocuous clinical presentation of a SMARCA4-deficient thoracic sarcoma arising in a patient with chronic empyema thoracis","volume":"51","author":"Nambirajan","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.bbcan.2026.189718_bb0190","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/PAS.0000000000001188","article-title":"SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses","volume":"43","author":"Perret","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0195","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/ng.2931","article-title":"Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type","volume":"46","author":"Witkowski","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189718_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107818","article-title":"Rare SMARCA4-deficient thoracic tumor: insights into molecular characterization and optimal therapeutics methods","volume":"192","author":"Shi","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0205","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf266","article-title":"Clinicopathological and molecular characteristics and treatment outcomes of SMARCA4-deficient thoracic tumors: a comprehensive analysis","volume":"30","author":"Liu","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189718_bb0210","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/10668969221095266","article-title":"SMARCA4-deficient undifferentiated uterine sarcoma: clinicopathological features of an emerging entity","volume":"31","author":"Nakra","year":"2023","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0215","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12672-023-00639-w","article-title":"Thoracic SMARCA4-deficient undifferentiated tumor","volume":"14","author":"Jiang","year":"2023","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0220","article-title":"SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses","volume":"43","author":"Raul","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0225","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0230","series-title":"Thoracic Tumours","author":"W.C.o.T.E. Board","year":"2021"},{"key":"10.1016\/j.bbcan.2026.189718_bb0235","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/onc.2009.4","article-title":"The SWI\/SNF complex and cancer","volume":"28","author":"Reisman","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189718_bb0240","article-title":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","volume":"26","author":"Adam J","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0245","article-title":"Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients","volume":"11","author":"Tharu M","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189718_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108817","article-title":"The immune desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors: spatial distribution characteristics and prognostic significance","volume":"210","author":"Wang","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0255","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/oncolo\/oyac040","article-title":"Immune-desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors","volume":"27","author":"Gantzer","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189718_bb0260","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/0008-5472.CAN-24-2054","article-title":"Mutation of SMARCA4 induces cancer cell-intrinsic defects in the enhancer landscape and resistance to immunotherapy","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0265","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer - biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0270","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf211","article-title":"SMARCA4 regulates inducible BRD4 genomic redistribution coupling intrinsic immunity and plasticity in epithelial injury-repair","volume":"53","author":"Xu","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0275","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbrc.2011.06.022","article-title":"BRG1 is indispensable for IFN-\u03b3-induced TRIM22 expression, which is dependent on the recruitment of IRF-1","volume":"410","author":"Wang","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189718_bb0280","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.1232458","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway","volume":"339","author":"Sun","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189718_bb0285","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni.3558","article-title":"Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing","volume":"17","author":"Chen","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0290","doi-asserted-by":"crossref","first-page":"14611","DOI":"10.1073\/pnas.0503070102","article-title":"Apical role for BRG1 in cytokine-induced promoter assembly","volume":"102","author":"Ni","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189718_bb0295","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1084\/jem.20030714","article-title":"The role of Brg1, a catalytic subunit of mammalian chromatin-remodeling complexes, in T cell development","volume":"198","author":"Gebuhr","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2026.189718_bb0300","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/ni.3170","article-title":"The chromatin remodeler Brg1 activates enhancer repertoires to establish B cell identity and modulate cell growth","volume":"16","author":"Bossen","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705848","article-title":"Brg1 supports B cell proliferation and germinal center formation through enhancer activation","volume":"12","author":"Schmiedel","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0310","article-title":"C-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors","volume":"7","author":"Balke-Want","year":"2026","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.bbcan.2026.189718_bb0315","article-title":"The SWI\/SNF-related, matrix associated, actin-dependent regulator of chromatin A4 core complex represses respiratory syncytial virus-induced syncytia formation and subepithelial myofibroblast transition","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2026.102633","article-title":"Dual PD-1\/IL-2R\u03b1 targeting restores CD8(+) T cell fitness via STAT5\/CD47 axis in SMARCA4-deficient NSCLC","author":"Shang","year":"2026","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.bbcan.2026.189718_bb0325","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41588-021-00884-1","article-title":"SWI\/SNF complexes as determinants of R-loop metabolism","volume":"53","author":"Abakir","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189718_bb0330","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","article-title":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0335","doi-asserted-by":"crossref","first-page":"14171","DOI":"10.1002\/cam4.6083","article-title":"Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer","volume":"12","author":"Liang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbcan.2026.189718_bb0340","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jtho.2025.01.016","article-title":"Gene copy deletion of STK11, KEAP1, and SMARCA4: clinicopathologic features and association with the outcomes of immunotherapy with or without chemotherapy in nonsquamous NSCLC","volume":"20","author":"Gandhi","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0345","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012288","article-title":"Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1, SMARCA4, and PTEN mutations","volume":"13","author":"Paredes","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0350","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189718_bb0355","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1158\/0008-5472.CAN-24-0044","article-title":"Loss of SMARCA4 leads to intron retention and generation of tumor-associated antigens in small cell carcinoma of the ovary, hypercalcemic type","volume":"85","author":"Raupach","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0360","article-title":"Case report: a durable response to camrelizumab and apatinib combination therapy in a heavily treated small cell carcinoma of the ovary, hypercalcemic type","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0365","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/jnci\/djx277","article-title":"Immune-active microenvironment in small cell carcinoma of the ovary, hypercalcemic type: rationale for immune checkpoint blockade","volume":"110","author":"Jelinic","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2026.189718_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.111770","article-title":"Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type","volume":"28","author":"Lang","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.bbcan.2026.189718_bb0375","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn2811","article-title":"SMARCA4 regulates the NK-mediated killing of senescent cells","volume":"11","author":"Reen","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2026.189718_bb0380","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk4851","article-title":"Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity","volume":"10","author":"Brodeur","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2026.189718_bb0385","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.6495","article-title":"Clinical outcomes and immune contexture in SMARCA4-deficient gastric cancer patients","volume":"268","author":"Sun","year":"2026","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/biom14080987","article-title":"The potential of immunotherapy for SMARCA4-deficient undifferentiated uterine sarcoma (SDUS)","volume":"14","author":"Yao","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbcan.2026.189718_bb0395","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4143\/crt.2023.1308","article-title":"Molecular and treatment characteristics of SMARCB1 or SMARCA4-deficient undifferentiated tumor: retrospective case series","volume":"56","author":"Kang","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.bbcan.2026.189718_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1020875","article-title":"Case report: a rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure","volume":"12","author":"Shi","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0405","article-title":"Conversion surgery for advanced thoracic SMARCA4-deficient undifferentiated tumor with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin treatment: a case report","volume":"2","author":"Kunimasa","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.bbcan.2026.189718_bb0410","article-title":"SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review","volume":"16","author":"Dong","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0415","doi-asserted-by":"crossref","first-page":"223","DOI":"10.7150\/jca.26978","article-title":"An in-depth look at small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): clinical implications from recent molecular findings","volume":"10","author":"Lu","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0420","article-title":"Marked response to nivolumab by a patient with SMARCA4-deficient undifferentiated urothelial carcinoma showing high PD-L1 expression: a case report","volume":"7","author":"Arihara","year":"2024","journal-title":"Cancer Rep. (Hoboken)"},{"key":"10.1016\/j.bbcan.2026.189718_bb0425","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/imt-2019-0142","article-title":"Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report","volume":"12","author":"Iijima","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bbcan.2026.189718_bb0430","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/1759-7714.13215","article-title":"Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: a case report","volume":"10","author":"Takada","year":"2019","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0435","first-page":"1","article-title":"SMARCA4-deficient epithelioid sarcoma revealed by comprehensive genomic profiling, leading to a notable response by nivolumab treatment","volume":"14","author":"Tokunaga","year":"2025","journal-title":"Int. Cancer Conf. J."},{"key":"10.1016\/j.bbcan.2026.189718_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217811","article-title":"SMARCA4: promises and challenges in the treatment of cancers","volume":"625","author":"Ye","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189718_bb0445","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.21037\/tlcr-24-691","article-title":"A retrospective study of the efficacy and safety of immune checkpoint inhibitors combined with chemotherapy for the treatment of SMARCA4-deficient thoracic tumors","volume":"13","author":"Wang","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e41128","article-title":"The impact of SMARCA4 loss in non-small cell lung cancer therapy","volume":"11","author":"Lombardi","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.bbcan.2026.189718_bb0455","article-title":"SMARCA4-deficient undifferentiated uterine sarcoma: a case report and literature review","volume":"104","author":"Wang","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bbcan.2026.189718_bb0460","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1177\/10668969221146204","article-title":"Switch\/sucrose non-fermentable complex-deficient rhabdoid carcinoma of stomach: a rare case report and literature review","volume":"31","author":"Chen","year":"2023","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0465","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/1066896919865944","article-title":"SMARCA4-deficient thoracic sarcoma: a case report and review of literature","volume":"28","author":"Stewart","year":"2020","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0470","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.21037\/tlcr-24-339","article-title":"SWItch\/sucrose nonfermentable complex-deficient pulmonary neoplasms: clinicopathologic characteristics and outcomes to radiotherapy and immunotherapy","volume":"13","author":"Gu","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0475","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gore.2014.12.003","article-title":"Radiotherapy for recurrent small cell carcinoma of the ovary: a case report and review of the literature","volume":"11","author":"Callegaro-Filho","year":"2015","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189718_bb0480","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1599569","article-title":"Case report: synergistic multimodal therapy in SMARCA4-deficient undifferentiated tumor: integrating chemotherapy, anti-angiogenesis immunotherapy, and radiotherapy for enhanced outcomes","volume":"15","author":"Xie","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0485","article-title":"Small intestine metastasis leads to the diagnosis of thoracic SMARCA4-deficient undifferentiated tumor: a case report","volume":"16","author":"Sanai","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.bbcan.2026.189718_bb0490","doi-asserted-by":"crossref","DOI":"10.1177\/01455613261425024","article-title":"Successful multimodal treatment of SMARCA4-deficient sinonasal carcinoma","author":"Ishigami","year":"2026","journal-title":"Ear Nose Throat J."},{"key":"10.1016\/j.bbcan.2026.189718_bb0495","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98811","article-title":"Frameshift events predict anti-PD-1\/L1 response in head and neck cancer","volume":"3","author":"Hanna","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbcan.2026.189718_bb0500","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.cllc.2022.03.005","article-title":"Efficacy of immune checkpoint inhibitors in SMARCA4-deficient thoracic tumor","volume":"23","author":"Shinno","year":"2022","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0505","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/1759-7714.13070","article-title":"Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: a case report","volume":"10","author":"Naito","year":"2019","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0515","doi-asserted-by":"crossref","DOI":"10.1177\/15330338251345377","article-title":"Retrospective insights into the clinicopathological features and treatment outcomes of thoracic SMARCA4-deficient tumors","volume":"24","author":"Chen","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.bbcan.2026.189718_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108498","article-title":"Efficacy of antiangiogenic therapy in patients with advanced SMARCA4-deficient thoracic tumor","volume":"202","author":"Shi","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0525","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1007\/s12672-025-03060-7","article-title":"Successful treatment with sintilimab for SMARCA4-deficient non-small cell lung carcinoma: two case reports","volume":"16","author":"Wang","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0530","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s00432-025-06284-w","article-title":"Long-term survival of a SMARCA4-deficient undifferentiated thoracic tumor with brain metastasis successfully treated with multimodal treatment: a case report and literature review","volume":"151","author":"Gan","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0535","doi-asserted-by":"crossref","DOI":"10.1111\/crj.70036","article-title":"Rapid response to penpulimab combined with anlotinib and chemotherapy in a thoracic SMARCA4-UT without PD-L1 expression: a case report and review of literature","volume":"18","author":"Wang","year":"2024","journal-title":"Clin. Respir. J."},{"key":"10.1016\/j.bbcan.2026.189718_bb0540","article-title":"First-line combination therapy of immunotherapy plus anti-angiogenic drug for thoracic SMARCA4-deficient undifferentiated tumors in AIDS: a case report and review of the literature","volume":"15","author":"Wei","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0545","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1200\/PO.20.00063","article-title":"Combined CDK4\/6 and PD-1 inhibition in refractory SMARCA4-deficient small-cell carcinoma of the ovary, hypercalcemic type","volume":"4","author":"Lee","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0550","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1159\/000515416","article-title":"Ipilimumab and pembrolizumab mixed response in a 41-year-old patient with SMARCA4-deficient thoracic sarcoma: an interdisciplinary case study","volume":"14","author":"An\u017ei\u010d","year":"2021","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0555","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000510323","article-title":"Cytology of SMARCA4-deficient thoracic neoplasms: comparative analysis of SMARCA4-deficient non-small cell lung carcinomas and SMARCA4-deficient thoracic sarcomas","volume":"65","author":"Nambirajan","year":"2021","journal-title":"Acta Cytol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0560","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","article-title":"Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors","volume":"66","author":"Lord","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bbcan.2026.189718_bb0565","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1073\/pnas.1316793111","article-title":"Functional epigenetics approach identifies BRM\/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers","volume":"111","author":"Hoffman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189718_bb0570","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/0008-5472.CAN-25-1141","article-title":"PRT3789 is a first-in-human SMARCA2-selective degrader that induces synthetic lethality in SMARCA4-mutated cancers","volume":"86","author":"Hulse","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0575","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1172\/JCI123557","article-title":"Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer","volume":"129","author":"Ding","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2026.189718_bb0580","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/2159-8290.CD-13-0799","article-title":"MAX inactivation in small cell lung cancer disrupts MYC-SWI\/SNF programs and is synthetic lethal with BRG1","volume":"4","author":"Romero","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189718_bb0585","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251385689","article-title":"Prolonged survival of thoracic SMARCA4-deficient undifferentiated tumor with immune-related cystitis: a case report and literature review","volume":"19","author":"Li","year":"2025","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.bbcan.2026.189718_bb0590","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1177329","article-title":"Case report: Nintedanib for immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with SMARCA4-mutant NSCLC: a case report","volume":"14","author":"Deng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0595","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189718_bb0600","article-title":"Detection of targetable genetic alterations in SMARCA4-deficient neoplasms of the lung - further evidence of a relationship between SMARCA4-deficient undifferentiated tumor and non-small cell carcinoma","volume":"167","author":"D\u2019Ambrosio","year":"2026","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0605","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189718_bb0610","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15180","article-title":"A molecular portrait of microsatellite instability across multiple cancers","volume":"8","author":"Cortes-Ciriano","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189718_bb0615","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189718_bb0620","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.18.00283","article-title":"Microsatellite instability is associated with the presence of lynch syndrome pan-cancer","volume":"37","author":"Latham","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0625","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189848","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma","volume":"12","author":"O\u2019Neil","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189718_bb0630","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012","volume":"119","author":"Mehra","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0635","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/cas.15650","article-title":"Pembrolizumab in Asian patients with microsatellite-instability-high\/mismatch-repair-deficient colorectal cancer","volume":"114","author":"Yoshino","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2026.189718_bb0640","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0645","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/2326-6066.CIR-19-0149","article-title":"Microsatellite-stable tumors with high mutational burden benefit from immunotherapy","volume":"7","author":"Goodman","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0650","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2026.189718_bb0655","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1158\/1078-0432.CCR-19-3663","article-title":"Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0660","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.21037\/tlcr-2025-556","article-title":"Potential efficacy of anti-angiogenic therapy combined with immunotherapy for advanced SMARCA4-deficient thoracic tumor: a retrospective study","volume":"14","author":"Liu","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189718_bb0665","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12957-025-04030-7","article-title":"A case report on SMARCA4 deficient cervical adenocarcinoma with high-grade squamous intraepithelial lesion","volume":"23","author":"Xu","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0670","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1111\/1759-7714.14547","article-title":"SMARCA4-deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: a case report","volume":"13","author":"Utsumi","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.bbcan.2026.189718_bb0675","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2217\/imt-2020-0311","article-title":"Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma","volume":"13","author":"Kawachi","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bbcan.2026.189718_bb0680","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1453895","article-title":"Long-term follow-up of combination therapy with pembrolizumab and anlotinib in thoracic SMARCA4-deficient undifferentiated tumor: a case report and molecular features","volume":"14","author":"Duan","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189718_bb0685","article-title":"Two cases of SMARCA4-deficient non-small cell lung cancer (NSCLC) with improved performance status (PS) after treatment with immune checkpoint inhibitors (ICIs)","volume":"15","author":"Koizumi","year":"2023","journal-title":"Cureus"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:15:36Z","timestamp":1790453736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":137,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0304419X26001903"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189718","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From molecular characteristics to clinical practice: current status and future prospects of immunotherapy for SMARCA4-deficient tumors","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189718"}}